TrialsgrambetaRCTs are beautiful

AMPLIFY

2013

Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis

In 5,395 patients with acute venous thromboembolism, apixaban was non-inferior to conventional heparin–warfarin therapy for recurrent VTE, with far less major bleeding.

Result

Recurrent VTE or VTE-related death
Absolute difference
0.4 points

The absolute difference is derived from the event rates.

Also reported: Major bleeding 0.6 % vs 1.8 % (RR 0.31).

Original publication
Subtopic
Venous thromboembolism
Design
Double-blind, double-dummy RCT
Relevance
Practice-defining: a trial the guidelines cite as evidence.
Source
Agnelli G, et al. N Engl J Med. 2013;369(9):799-808.doi 10.1056/NEJMoa1302507

Discussion & critique

A single-drug oral regimen with no heparin lead-in. The 69 % reduction in major bleeding is the headline; AMPLIFY-EXT extended the low-dose secondary-prevention story.

Discussed in podcasts